Pfizer’s Friendly Tack: McKinnell Shares Credit With Hassan, Offers No. 2 Spot
Executive Summary
Pfizer's $60 bil. offer for Pharmacia could be a landmark event in the remaking of the Pfizer image, as well as a large-scale strategic move to broaden Pfizer's product line into new specialties and deepen the pipeline
You may also be interested in...
Pfizer’s Shedlarz retires
Pfizer Vice Chairman David Shedlarz will retire at the end of the year, the company announces Oct. 25. Shedlarz was considered a potential successor to then-CEO Hank McKinnell when he was promoted to vice chairman, along with Karen Katen and current CEO Jeffrey Kindler in 2006 (1"The Pink Sheet" Feb. 28, 2005, p. 20). Shedlarz is noted for leading the integration of the Pharmacia acquisition in 2003, which has been a challenge for Pfizer (2"The Pink Sheet" July 22, 2002, p. 3). Shedlarz joined the company in 1976; he served 10 years as CFO, and most recently led strategic planning and business development...
Pfizer’s Shedlarz retires
Pfizer Vice Chairman David Shedlarz will retire at the end of the year, the company announces Oct. 25. Shedlarz was considered a potential successor to then-CEO Hank McKinnell when he was promoted to vice chairman, along with Karen Katen and current CEO Jeffrey Kindler in 2006 (1"The Pink Sheet" Feb. 28, 2005, p. 20). Shedlarz is noted for leading the integration of the Pharmacia acquisition in 2003, which has been a challenge for Pfizer (2"The Pink Sheet" July 22, 2002, p. 3). Shedlarz joined the company in 1976; he served 10 years as CFO, and most recently led strategic planning and business development...
Pfizer Considering Biotech Acquisitions; “Probably No” Big Mergers
Pfizer is returning to acquisition mode, but with an eye on building its biotechnology presence rather than another major pharmaceutical merger